,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2017', 'fs': 'Nov 2017', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQFUAY'}, 'Id': 'a0P2P0000059wQFUAY', 'Event_Date__c': '2017-11-10', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Nov 2017', 'Status_History__c': 'a132P000000ArMoQAK'}, 'change': None}]",Nov 2017,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQGUAY'}, 'Id': 'a0P2P0000059wQGUAY', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPDQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQIUAY'}, 'Id': 'a0P2P0000059wQIUAY', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPZQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQJUAY'}, 'Id': 'a0P2P0000059wQJUAY', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPhQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Subcommittee recommended that vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma be funded with a <b>medium</b> priority subject to the following Special Authority criteria: </p><p><br></p><p><span style=""font-size: 10pt;"">Special Authority for Subsidy – PCT only</span></p><p><span style=""font-size: 10pt;"">Initial application – only from a medical oncologist or radiation oncologist or medical practitioner on the recommendation of a medical oncologist or radiation oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 10pt;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has locally advanced or metastatic basal cell carcinoma; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Surgery is considered to be clinically inappropriate (see Note); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Radiotherapy is considered clinically inappropriate (see Note); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient is intolerant or contraindicated to platinum- or taxane-based chemotherapy.</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p><span style=""font-size: 10pt;"">Renewal application– only from a medical oncologist or radiation oncologist or medical practitioner on the recommendation of a medical oncologist or radiation oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 10pt;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has locally advanced or metastatic basal cell carcinoma; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">There is no evidence of disease progression; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">The treatment remains appropriate and the patient is benefitting from treatment.</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p><span style=""font-size: 10pt;"">Note: “inappropriate for surgery” is defined as curative resection unlikely, would result in substantial morbidity or deformity or require complicated reconstructive surgery (removal of all or part of facial structure or requirement for limb amputation or free tissue transfer), or medical contraindication for surgery. “inappropriate for radiotherapy” is defined as hypersensitivity to radiation due to genetic syndrome such as Gorlin Syndrome, limitations due to location of tumour or cumulative prior radiotherapy dose, or progressive disease despite prior irradiation of locally advanced BCC.</span></p><h2 style=""text-align: justify;""><br></h2><p><br></p>', 'fs': '<p>The Subcommittee recommended that vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma be funded with a <b>medium</b> priority subject to the following Special Authority criteria: </p><p><br></p><p><span style=""font-size: 10pt;"">Special Authority for Subsidy – PCT only</span></p><p><span style=""font-size: 10pt;"">Initial application – only from a medical oncologist or radiation oncologist or medical practitioner on the recommendation of a medical oncologist or radiation oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 10pt;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has locally advanced or metastatic basal cell carcinoma; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Surgery is considered to be clinically inappropriate (see Note); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Radiotherapy is considered clinically inappropriate (see Note); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient is intolerant or contraindicated to platinum- or taxane-based chemotherapy.</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p><span style=""font-size: 10pt;"">Renewal application– only from a medical oncologist or radiation oncologist or medical practitioner on the recommendation of a medical oncologist or radiation oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 10pt;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has locally advanced or metastatic basal cell carcinoma; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">There is no evidence of disease progression; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">The treatment remains appropriate and the patient is benefitting from treatment.</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p><span style=""font-size: 10pt;"">Note: “inappropriate for surgery” is defined as curative resection unlikely, would result in substantial morbidity or deformity or require complicated reconstructive surgery (removal of all or part of facial structure or requirement for limb amputation or free tissue transfer), or medical contraindication for surgery. “inappropriate for radiotherapy” is defined as hypersensitivity to radiation due to genetic syndrome such as Gorlin Syndrome, limitations due to location of tumour or cumulative prior radiotherapy dose, or progressive disease despite prior irradiation of locally advanced BCC.</span></p><h2 style=""text-align: justify;""><br></h2><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Subcommittee noted that a funding application for vismodegib for the treatment of basal cell carcinoma (BCC) in patients with Gorlin syndrome was recommended for decline by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a>. The Subcommittee noted that at this meeting PTAC considered that vismodegib was a high cost medicine, that the evidence in patients with Gorlin syndrome was of weak strength and quality, that the agent is associated with significant toxicity, and that it would not be appropriate to limit funding just to patients with Gorlin Syndrome.</p><p><br></p><p>The Subcommittee noted that an updated application for vismodegib for the treatment of patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">February 2018</a>. The Subcommittee noted that at this meeting PTAC considered that there could be a place for vismodegib for individuals with extreme disease but noted that there was no evidence in this setting and that appropriately defining access criteria to target these patients would be difficult. The Subcommittee noted that PTAC declined the application and recommended that it be referred to CaTSoP for advice regarding alternative treatment options, defining the patient population that would benefit most from vismodegib, and the likely number of patients who would be eligible for treatment.</p><p><br></p><p>The Subcommittee noted that BCC is common in New Zealand, but that metastatic BCC occurs rarely. The Subcommittee considered that estimating the number of patients with locally advanced BCC is difficult as there is no widely accepted definition of locally advanced disease. The Subcommittee considered that there is likely to be a maximum of 50 patients per year with metastatic BCC, and up to 200 per year with locally advanced BCC where surgery and/or radiation therapy are not appropriate depending on how this is defined.</p><p><br></p><p>The Subcommittee considered that the treatment options for patients with metastatic BCC and locally advanced BCC not amenable to surgery or radiotherapy are limited to platinum- or taxane-based chemotherapy; however, the Subcommittee considered that many patients with locally advanced or metastatic BCC would not be fit enough for chemotherapy due to age or health status. The Subcommittee considered that the only treatment option for these patients would be palliative care.</p><p><br></p><p>The Subcommittee considered that evidence for the efficacy of platinum- or taxane-based chemotherapy is sparse but noted a review of 53 cases where patients with BCC were treated with cytotoxic therapy which reported a response rate of 77%, a complete response rate of 45%, and a median survival of 22 months (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/2138485"" target=""_blank"">Pfeiffer et al. Eur J Cancer. 1990;26:73-7</a>).\xa0</p><p><br></p><p>The Subcommittee noted that vismodegib is an inhibitor of the Hedgehog pathway which is involved in the maintenance of somatic stem cells and pluripotent cells which play an important role in tissue repair. The Subcommittee noted that the Hedgehog pathway is abnormally activated in 95% of sporadic BCCs, resulting in cell division and tumorigenesis.</p><p><br></p><p><span style=""color: black;""></span>The Subcommittee noted a systematic review of 8 studies involving 704 evaluable patients that investigated the clinical experience with the Hedgehog pathway inhibitors vismodegib and sonidegib for the treatment of locally advanced or metastatic BCC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27096888"" target=""_blank"">Jacobsen et al. JAMA Dermatol. 2016;152:816-24</a>). The Subcommittee noted that the studies included were mostly single-arm early phase trials, case series, or retrospective medical record reviews. The Subcommittee noted that the weighted average objective response rate for vismodegib was 64.7% (95% CI 63.7% to 65.6%) for patients with locally advanced BCC and 33.6% (95% CI 33.1% to 34.2%) for patients with metastatic BCC. The Subcommittee noted that the mean weighted duration of vismodegib exposure was 35.8 weeks (95% CI 35.1 to 36.5 weeks). </p><p><br></p><p>The Subcommittee noted the single-arm, open label, Phase 2 STEVIE trial that investigated the safety of vismodegib in 1215 patients with advanced basal cell carcinoma in a situation similar to routine practice (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/25981813"" target=""_blank"">Basset-Seguin et al. Lancet Oncol. 2015;16:729-36</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29073584"" target=""_blank"">Basset-Seguin et al. Eur J Cancer. 2017;86:334-48</a>). The Subcommittee noted that the median duration of treatment with vismodegib at the time of the primary analysis was 8.6 months. The Subcommittee noted that in patients with locally advanced disease, the response rate was 68.5% (95% CI 65.7% to 71.3%) and the median duration of response was 23.0 months. The Subcommittee noted that in patients with metastatic disease, the response rate was 36.9% (95% CI 26.6% to 48.1%) and the median duration of response was 13.9 months.</p><p><br></p><p>The Subcommittee noted that 98% of patients in the STEVIE trial reported a treatment-emergent adverse event; the most common being muscle spasms (66%), alopecia (62%), dysgeusia (55%), decreased weight (41%), decreased appetite (25%), and asthenia (24%). The Subcommittee noted that 31% of patients discontinued due to treatment-emergent adverse events.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a secondary analysis of the STEVIE trial which used the Skindex-16 and MD Anderson Symptom Inventory (MDASI) instruments to assess health-related quality of life among patients with BCC treated with vismodegib (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30698147"" target=""_blank"">Hansson et al. Eur J Dermatol. 2018;28:775-83</a>). The Subcommittee noted that there was a clinically meaningful improvement in emotional well-being in patients with locally advanced BCC treated with vismodegib, but no difference in symptom and functional scores. The Subcommittee noted that there was no clinically meaningful improvement or deterioration in any domain for patients with metastatic BCC receiving vismodegib.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the single-arm, open label, PHASE 2 ERIVANCE study that investigated the long-term safety and efficacy of vismodegib in 104 patients with advanced BCC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22670903"" target=""_blank"">Seculik et al. N Engl J Med. 2012;366:2171-9</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/25981002"" target=""_blank"">Sekulic et al. J Am Acad Dermatol. 2015;72:1021-6</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28511673"" target=""_blank"">Sekulic et al. BMC Cancer. 2017;17:332</a>). The Subcommittee noted that the median duration of treatment at the time of the long-term update of ERIVANCE was 12.7 months in patients with locally advanced disease and 12.9 months in patients with metastatic disease. The Subcommittee noted that in patients with locally advanced disease, the objective response rate was 60.3% (95% CI 47.2% to 71.7%) and the median duration of response was 26.2 months. The Subcommittee noted that in patients with metastatic disease, the objective response rate was 48.5% (95% CI 30.8% to 66.2%) and the median duration of response was 14.8 months.</p><p><br></p><p>The Subcommittee noted that all patients in ERIVANCE experienced at least one treatment-emergent adverse event, the most common being muscle spasms (71.2%), alopecia (66.3%), dysgeusia (55.8%), weight decrease (51.9%), fatigue (43.3%), and nausea (32.7%). The Subcommittee noted that 21.2% of patients discontinued treatment due to adverse events.</p><p><br></p><p>The Subcommittee considered that vismodegib is associated with some toxicity, and that this is likely to limit the duration of time patients receive treatment and has the potential to result in additional health sector costs for managing adverse events. The Subcommittee considered that patients receiving vismodegib would be seen by their treating physician routinely due to toxicity.</p><p><br></p><p>The Subcommittee considered that the majority of the evidence available for vismodegib is from uncontrolled single-arm early phase trials or real-world observational data from access programs, and that it is unlikely that Phase 3 trials will ever be conducted. The Subcommittee considered that the evidence is of low quality and demonstrates only a moderate benefit; however, it was also noted that advanced BCC is a mutilating disease for which there are limited treatment options available.</p><p><br></p><p>The Subcommittee considered that if it were funded, access to vismodegib should be restricted to patients with locally advanced or metastatic BCC for whom surgery and radiotherapy are inappropriate and platinum- or taxane-based chemotherapy is contraindicated. The Subcommittee considered that approximately ten patients per year would fit these criteria.</p><p><br></p><p>The Subcommittee considered there would likely be a preference for use of vismodegib over further surgery or other types of chemotherapy, even with its associated toxicities. The Subcommittee noted anecdotal reports of various alternate dosage regimens, such as intermittent treatment, being used with the aim of reducing toxicity. </p><p><br></p><p>The Subcommittee considered that given the previously outlined difficulty in clearly and appropriately defining a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate there would likely be a significant fiscal risk associated with funding of vismodegib.</p>', 'fs': '<p>The Subcommittee noted that a funding application for vismodegib for the treatment of basal cell carcinoma (BCC) in patients with Gorlin syndrome was recommended for decline by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a>. The Subcommittee noted that at this meeting PTAC considered that vismodegib was a high cost medicine, that the evidence in patients with Gorlin syndrome was of weak strength and quality, that the agent is associated with significant toxicity, and that it would not be appropriate to limit funding just to patients with Gorlin Syndrome.</p><p><br></p><p>The Subcommittee noted that an updated application for vismodegib for the treatment of patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">February 2018</a>. The Subcommittee noted that at this meeting PTAC considered that there could be a place for vismodegib for individuals with extreme disease but noted that there was no evidence in this setting and that appropriately defining access criteria to target these patients would be difficult. The Subcommittee noted that PTAC declined the application and recommended that it be referred to CaTSoP for advice regarding alternative treatment options, defining the patient population that would benefit most from vismodegib, and the likely number of patients who would be eligible for treatment.</p><p><br></p><p>The Subcommittee noted that BCC is common in New Zealand, but that metastatic BCC occurs rarely. The Subcommittee considered that estimating the number of patients with locally advanced BCC is difficult as there is no widely accepted definition of locally advanced disease. The Subcommittee considered that there is likely to be a maximum of 50 patients per year with metastatic BCC, and up to 200 per year with locally advanced BCC where surgery and/or radiation therapy are not appropriate depending on how this is defined.</p><p><br></p><p>The Subcommittee considered that the treatment options for patients with metastatic BCC and locally advanced BCC not amenable to surgery or radiotherapy are limited to platinum- or taxane-based chemotherapy; however, the Subcommittee considered that many patients with locally advanced or metastatic BCC would not be fit enough for chemotherapy due to age or health status. The Subcommittee considered that the only treatment option for these patients would be palliative care.</p><p><br></p><p>The Subcommittee considered that evidence for the efficacy of platinum- or taxane-based chemotherapy is sparse but noted a review of 53 cases where patients with BCC were treated with cytotoxic therapy which reported a response rate of 77%, a complete response rate of 45%, and a median survival of 22 months (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/2138485"" target=""_blank"">Pfeiffer et al. Eur J Cancer. 1990;26:73-7</a>).\xa0</p><p><br></p><p>The Subcommittee noted that vismodegib is an inhibitor of the Hedgehog pathway which is involved in the maintenance of somatic stem cells and pluripotent cells which play an important role in tissue repair. The Subcommittee noted that the Hedgehog pathway is abnormally activated in 95% of sporadic BCCs, resulting in cell division and tumorigenesis.</p><p><br></p><p><span style=""color: black;""></span>The Subcommittee noted a systematic review of 8 studies involving 704 evaluable patients that investigated the clinical experience with the Hedgehog pathway inhibitors vismodegib and sonidegib for the treatment of locally advanced or metastatic BCC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27096888"" target=""_blank"">Jacobsen et al. JAMA Dermatol. 2016;152:816-24</a>). The Subcommittee noted that the studies included were mostly single-arm early phase trials, case series, or retrospective medical record reviews. The Subcommittee noted that the weighted average objective response rate for vismodegib was 64.7% (95% CI 63.7% to 65.6%) for patients with locally advanced BCC and 33.6% (95% CI 33.1% to 34.2%) for patients with metastatic BCC. The Subcommittee noted that the mean weighted duration of vismodegib exposure was 35.8 weeks (95% CI 35.1 to 36.5 weeks). </p><p><br></p><p>The Subcommittee noted the single-arm, open label, Phase 2 STEVIE trial that investigated the safety of vismodegib in 1215 patients with advanced basal cell carcinoma in a situation similar to routine practice (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/25981813"" target=""_blank"">Basset-Seguin et al. Lancet Oncol. 2015;16:729-36</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29073584"" target=""_blank"">Basset-Seguin et al. Eur J Cancer. 2017;86:334-48</a>). The Subcommittee noted that the median duration of treatment with vismodegib at the time of the primary analysis was 8.6 months. The Subcommittee noted that in patients with locally advanced disease, the response rate was 68.5% (95% CI 65.7% to 71.3%) and the median duration of response was 23.0 months. The Subcommittee noted that in patients with metastatic disease, the response rate was 36.9% (95% CI 26.6% to 48.1%) and the median duration of response was 13.9 months.</p><p><br></p><p>The Subcommittee noted that 98% of patients in the STEVIE trial reported a treatment-emergent adverse event; the most common being muscle spasms (66%), alopecia (62%), dysgeusia (55%), decreased weight (41%), decreased appetite (25%), and asthenia (24%). The Subcommittee noted that 31% of patients discontinued due to treatment-emergent adverse events.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a secondary analysis of the STEVIE trial which used the Skindex-16 and MD Anderson Symptom Inventory (MDASI) instruments to assess health-related quality of life among patients with BCC treated with vismodegib (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30698147"" target=""_blank"">Hansson et al. Eur J Dermatol. 2018;28:775-83</a>). The Subcommittee noted that there was a clinically meaningful improvement in emotional well-being in patients with locally advanced BCC treated with vismodegib, but no difference in symptom and functional scores. The Subcommittee noted that there was no clinically meaningful improvement or deterioration in any domain for patients with metastatic BCC receiving vismodegib.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the single-arm, open label, PHASE 2 ERIVANCE study that investigated the long-term safety and efficacy of vismodegib in 104 patients with advanced BCC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22670903"" target=""_blank"">Seculik et al. N Engl J Med. 2012;366:2171-9</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/25981002"" target=""_blank"">Sekulic et al. J Am Acad Dermatol. 2015;72:1021-6</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28511673"" target=""_blank"">Sekulic et al. BMC Cancer. 2017;17:332</a>). The Subcommittee noted that the median duration of treatment at the time of the long-term update of ERIVANCE was 12.7 months in patients with locally advanced disease and 12.9 months in patients with metastatic disease. The Subcommittee noted that in patients with locally advanced disease, the objective response rate was 60.3% (95% CI 47.2% to 71.7%) and the median duration of response was 26.2 months. The Subcommittee noted that in patients with metastatic disease, the objective response rate was 48.5% (95% CI 30.8% to 66.2%) and the median duration of response was 14.8 months.</p><p><br></p><p>The Subcommittee noted that all patients in ERIVANCE experienced at least one treatment-emergent adverse event, the most common being muscle spasms (71.2%), alopecia (66.3%), dysgeusia (55.8%), weight decrease (51.9%), fatigue (43.3%), and nausea (32.7%). The Subcommittee noted that 21.2% of patients discontinued treatment due to adverse events.</p><p><br></p><p>The Subcommittee considered that vismodegib is associated with some toxicity, and that this is likely to limit the duration of time patients receive treatment and has the potential to result in additional health sector costs for managing adverse events. The Subcommittee considered that patients receiving vismodegib would be seen by their treating physician routinely due to toxicity.</p><p><br></p><p>The Subcommittee considered that the majority of the evidence available for vismodegib is from uncontrolled single-arm early phase trials or real-world observational data from access programs, and that it is unlikely that Phase 3 trials will ever be conducted. The Subcommittee considered that the evidence is of low quality and demonstrates only a moderate benefit; however, it was also noted that advanced BCC is a mutilating disease for which there are limited treatment options available.</p><p><br></p><p>The Subcommittee considered that if it were funded, access to vismodegib should be restricted to patients with locally advanced or metastatic BCC for whom surgery and radiotherapy are inappropriate and platinum- or taxane-based chemotherapy is contraindicated. The Subcommittee considered that approximately ten patients per year would fit these criteria.</p><p><br></p><p>The Subcommittee considered there would likely be a preference for use of vismodegib over further surgery or other types of chemotherapy, even with its associated toxicities. The Subcommittee noted anecdotal reports of various alternate dosage regimens, such as intermittent treatment, being used with the aim of reducing toxicity. </p><p><br></p><p>The Subcommittee considered that given the previously outlined difficulty in clearly and appropriately defining a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate there would likely be a significant fiscal risk associated with funding of vismodegib.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Subcommittee reviewed a funding application for vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma. </p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>The Subcommittee reviewed a funding application for vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma. </p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to item 2, vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma (BCC), the Committee noted that CaTSoP had recommended funding for patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate with medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CaTSoP considered where patients are not amenable to surgery or radiotherapy, there were limited treatment options; for many patients the only treatment option was palliative care, as they would not be fit enough for chemotherapy due to age or poor health status. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that while CaTSoP had proposed a Special Authority criteria with a view to defining a population that would benefit most from vismodegib treatment, CaTSoP had also indicated there would likely be a significant fiscal risk associated with funding of vismodegib, related to the difficulty in being able to clearly and appropriately define a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate. The Committee shared CaTSoP’s concerns regarding the difficulties with population definition and the associated potential risk of use of vismodegib beyond the intended population. Members considered this would likely be due to both variation in interpretation of the proposed Special Authority criteria and, as CaTSoP had identified, a preference for using vismodegib instead of surgery/radiotherapy should vismodegib be funded.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in practice, vismodegib may be used with alternate dosing regimens to those in the primary clinical trial evidence, such as intermittent dosing schedules with the aim of reducing toxicity. The Committee noted that evidence for use of alternate dosing approaches was poor, coming solely from anecdotal case reports.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had previously considered the application for vismodegib at its meetings in May 2015 and February 2018. At these meetings, PTAC had considered the evidence for the use of vismodegib in the treatment of locally advanced or metastatic BCC was of weak strength and quality, use was associated with significant toxicities, it was a high-cost medicine, and PTAC had recommended that funding of vismodegib for BCC patients be declined.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s careful consideration and advice about vismodegib. However, based on the difficulties objectively defining the clinical population eligible for the treatment should it be funded; the high level of fiscal and clinical risks associated with the use of this agent in a clinical population with less extreme disease manifestations; the limited evidence base; and finally the very high price sought by the supplier; the Committee did not consider that its previous recommendation regarding the funding of vismodegib should be changed.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to item 2, vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma (BCC), the Committee noted that CaTSoP had recommended funding for patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate with medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CaTSoP considered where patients are not amenable to surgery or radiotherapy, there were limited treatment options; for many patients the only treatment option was palliative care, as they would not be fit enough for chemotherapy due to age or poor health status. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that while CaTSoP had proposed a Special Authority criteria with a view to defining a population that would benefit most from vismodegib treatment, CaTSoP had also indicated there would likely be a significant fiscal risk associated with funding of vismodegib, related to the difficulty in being able to clearly and appropriately define a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate. The Committee shared CaTSoP’s concerns regarding the difficulties with population definition and the associated potential risk of use of vismodegib beyond the intended population. Members considered this would likely be due to both variation in interpretation of the proposed Special Authority criteria and, as CaTSoP had identified, a preference for using vismodegib instead of surgery/radiotherapy should vismodegib be funded.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in practice, vismodegib may be used with alternate dosing regimens to those in the primary clinical trial evidence, such as intermittent dosing schedules with the aim of reducing toxicity. The Committee noted that evidence for use of alternate dosing approaches was poor, coming solely from anecdotal case reports.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had previously considered the application for vismodegib at its meetings in May 2015 and February 2018. At these meetings, PTAC had considered the evidence for the use of vismodegib in the treatment of locally advanced or metastatic BCC was of weak strength and quality, use was associated with significant toxicities, it was a high-cost medicine, and PTAC had recommended that funding of vismodegib for BCC patients be declined.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s careful consideration and advice about vismodegib. However, based on the difficulties objectively defining the clinical population eligible for the treatment should it be funded; the high level of fiscal and clinical risks associated with the use of this agent in a clinical population with less extreme disease manifestations; the limited evidence base; and finally the very high price sought by the supplier; the Committee did not consider that its previous recommendation regarding the funding of vismodegib should be changed.\xa0</p>', 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">CaTSoP Subcommittee Record</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">CaTSoP Subcommittee Record</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQLUAY'}, 'Id': 'a0P2P0000059wQLUAY', 'Event_Date__c': '2019-10-29', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">CaTSoP Subcommittee Record</a></p>', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2019', 'Published_Recommendation__c': '<p>The Subcommittee recommended that vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma be funded with a <b>medium</b> priority subject to the following Special Authority criteria: </p><p><br></p><p><span style=""font-size: 10pt;"">Special Authority for Subsidy – PCT only</span></p><p><span style=""font-size: 10pt;"">Initial application – only from a medical oncologist or radiation oncologist or medical practitioner on the recommendation of a medical oncologist or radiation oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 10pt;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has locally advanced or metastatic basal cell carcinoma; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Surgery is considered to be clinically inappropriate (see Note); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Radiotherapy is considered clinically inappropriate (see Note); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient is intolerant or contraindicated to platinum- or taxane-based chemotherapy.</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p><span style=""font-size: 10pt;"">Renewal application– only from a medical oncologist or radiation oncologist or medical practitioner on the recommendation of a medical oncologist or radiation oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 10pt;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has locally advanced or metastatic basal cell carcinoma; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">There is no evidence of disease progression; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">The treatment remains appropriate and the patient is benefitting from treatment.</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p><span style=""font-size: 10pt;"">Note: “inappropriate for surgery” is defined as curative resection unlikely, would result in substantial morbidity or deformity or require complicated reconstructive surgery (removal of all or part of facial structure or requirement for limb amputation or free tissue transfer), or medical contraindication for surgery. “inappropriate for radiotherapy” is defined as hypersensitivity to radiation due to genetic syndrome such as Gorlin Syndrome, limitations due to location of tumour or cumulative prior radiotherapy dose, or progressive disease despite prior irradiation of locally advanced BCC.</span></p><h2 style=""text-align: justify;""><br></h2><p><br></p>', 'Published_Application__c': '<p>The Subcommittee reviewed a funding application for vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma. </p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>The Subcommittee noted that a funding application for vismodegib for the treatment of basal cell carcinoma (BCC) in patients with Gorlin syndrome was recommended for decline by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a>. The Subcommittee noted that at this meeting PTAC considered that vismodegib was a high cost medicine, that the evidence in patients with Gorlin syndrome was of weak strength and quality, that the agent is associated with significant toxicity, and that it would not be appropriate to limit funding just to patients with Gorlin Syndrome.</p><p><br></p><p>The Subcommittee noted that an updated application for vismodegib for the treatment of patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">February 2018</a>. The Subcommittee noted that at this meeting PTAC considered that there could be a place for vismodegib for individuals with extreme disease but noted that there was no evidence in this setting and that appropriately defining access criteria to target these patients would be difficult. The Subcommittee noted that PTAC declined the application and recommended that it be referred to CaTSoP for advice regarding alternative treatment options, defining the patient population that would benefit most from vismodegib, and the likely number of patients who would be eligible for treatment.</p><p><br></p><p>The Subcommittee noted that BCC is common in New Zealand, but that metastatic BCC occurs rarely. The Subcommittee considered that estimating the number of patients with locally advanced BCC is difficult as there is no widely accepted definition of locally advanced disease. The Subcommittee considered that there is likely to be a maximum of 50 patients per year with metastatic BCC, and up to 200 per year with locally advanced BCC where surgery and/or radiation therapy are not appropriate depending on how this is defined.</p><p><br></p><p>The Subcommittee considered that the treatment options for patients with metastatic BCC and locally advanced BCC not amenable to surgery or radiotherapy are limited to platinum- or taxane-based chemotherapy; however, the Subcommittee considered that many patients with locally advanced or metastatic BCC would not be fit enough for chemotherapy due to age or health status. The Subcommittee considered that the only treatment option for these patients would be palliative care.</p><p><br></p><p>The Subcommittee considered that evidence for the efficacy of platinum- or taxane-based chemotherapy is sparse but noted a review of 53 cases where patients with BCC were treated with cytotoxic therapy which reported a response rate of 77%, a complete response rate of 45%, and a median survival of 22 months (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/2138485"" target=""_blank"">Pfeiffer et al. Eur J Cancer. 1990;26:73-7</a>).\xa0</p><p><br></p><p>The Subcommittee noted that vismodegib is an inhibitor of the Hedgehog pathway which is involved in the maintenance of somatic stem cells and pluripotent cells which play an important role in tissue repair. The Subcommittee noted that the Hedgehog pathway is abnormally activated in 95% of sporadic BCCs, resulting in cell division and tumorigenesis.</p><p><br></p><p><span style=""color: black;""></span>The Subcommittee noted a systematic review of 8 studies involving 704 evaluable patients that investigated the clinical experience with the Hedgehog pathway inhibitors vismodegib and sonidegib for the treatment of locally advanced or metastatic BCC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27096888"" target=""_blank"">Jacobsen et al. JAMA Dermatol. 2016;152:816-24</a>). The Subcommittee noted that the studies included were mostly single-arm early phase trials, case series, or retrospective medical record reviews. The Subcommittee noted that the weighted average objective response rate for vismodegib was 64.7% (95% CI 63.7% to 65.6%) for patients with locally advanced BCC and 33.6% (95% CI 33.1% to 34.2%) for patients with metastatic BCC. The Subcommittee noted that the mean weighted duration of vismodegib exposure was 35.8 weeks (95% CI 35.1 to 36.5 weeks). </p><p><br></p><p>The Subcommittee noted the single-arm, open label, Phase 2 STEVIE trial that investigated the safety of vismodegib in 1215 patients with advanced basal cell carcinoma in a situation similar to routine practice (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/25981813"" target=""_blank"">Basset-Seguin et al. Lancet Oncol. 2015;16:729-36</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29073584"" target=""_blank"">Basset-Seguin et al. Eur J Cancer. 2017;86:334-48</a>). The Subcommittee noted that the median duration of treatment with vismodegib at the time of the primary analysis was 8.6 months. The Subcommittee noted that in patients with locally advanced disease, the response rate was 68.5% (95% CI 65.7% to 71.3%) and the median duration of response was 23.0 months. The Subcommittee noted that in patients with metastatic disease, the response rate was 36.9% (95% CI 26.6% to 48.1%) and the median duration of response was 13.9 months.</p><p><br></p><p>The Subcommittee noted that 98% of patients in the STEVIE trial reported a treatment-emergent adverse event; the most common being muscle spasms (66%), alopecia (62%), dysgeusia (55%), decreased weight (41%), decreased appetite (25%), and asthenia (24%). The Subcommittee noted that 31% of patients discontinued due to treatment-emergent adverse events.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a secondary analysis of the STEVIE trial which used the Skindex-16 and MD Anderson Symptom Inventory (MDASI) instruments to assess health-related quality of life among patients with BCC treated with vismodegib (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30698147"" target=""_blank"">Hansson et al. Eur J Dermatol. 2018;28:775-83</a>). The Subcommittee noted that there was a clinically meaningful improvement in emotional well-being in patients with locally advanced BCC treated with vismodegib, but no difference in symptom and functional scores. The Subcommittee noted that there was no clinically meaningful improvement or deterioration in any domain for patients with metastatic BCC receiving vismodegib.</p><p><br></p><p><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted the single-arm, open label, PHASE 2 ERIVANCE study that investigated the long-term safety and efficacy of vismodegib in 104 patients with advanced BCC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22670903"" target=""_blank"">Seculik et al. N Engl J Med. 2012;366:2171-9</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/25981002"" target=""_blank"">Sekulic et al. J Am Acad Dermatol. 2015;72:1021-6</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28511673"" target=""_blank"">Sekulic et al. BMC Cancer. 2017;17:332</a>). The Subcommittee noted that the median duration of treatment at the time of the long-term update of ERIVANCE was 12.7 months in patients with locally advanced disease and 12.9 months in patients with metastatic disease. The Subcommittee noted that in patients with locally advanced disease, the objective response rate was 60.3% (95% CI 47.2% to 71.7%) and the median duration of response was 26.2 months. The Subcommittee noted that in patients with metastatic disease, the objective response rate was 48.5% (95% CI 30.8% to 66.2%) and the median duration of response was 14.8 months.</p><p><br></p><p>The Subcommittee noted that all patients in ERIVANCE experienced at least one treatment-emergent adverse event, the most common being muscle spasms (71.2%), alopecia (66.3%), dysgeusia (55.8%), weight decrease (51.9%), fatigue (43.3%), and nausea (32.7%). The Subcommittee noted that 21.2% of patients discontinued treatment due to adverse events.</p><p><br></p><p>The Subcommittee considered that vismodegib is associated with some toxicity, and that this is likely to limit the duration of time patients receive treatment and has the potential to result in additional health sector costs for managing adverse events. The Subcommittee considered that patients receiving vismodegib would be seen by their treating physician routinely due to toxicity.</p><p><br></p><p>The Subcommittee considered that the majority of the evidence available for vismodegib is from uncontrolled single-arm early phase trials or real-world observational data from access programs, and that it is unlikely that Phase 3 trials will ever be conducted. The Subcommittee considered that the evidence is of low quality and demonstrates only a moderate benefit; however, it was also noted that advanced BCC is a mutilating disease for which there are limited treatment options available.</p><p><br></p><p>The Subcommittee considered that if it were funded, access to vismodegib should be restricted to patients with locally advanced or metastatic BCC for whom surgery and radiotherapy are inappropriate and platinum- or taxane-based chemotherapy is contraindicated. The Subcommittee considered that approximately ten patients per year would fit these criteria.</p><p><br></p><p>The Subcommittee considered there would likely be a preference for use of vismodegib over further surgery or other types of chemotherapy, even with its associated toxicities. The Subcommittee noted anecdotal reports of various alternate dosage regimens, such as intermittent treatment, being used with the aim of reducing toxicity. </p><p><br></p><p>The Subcommittee considered that given the previously outlined difficulty in clearly and appropriately defining a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate there would likely be a significant fiscal risk associated with funding of vismodegib.</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to item 2, vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma (BCC), the Committee noted that CaTSoP had recommended funding for patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate with medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CaTSoP considered where patients are not amenable to surgery or radiotherapy, there were limited treatment options; for many patients the only treatment option was palliative care, as they would not be fit enough for chemotherapy due to age or poor health status. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that while CaTSoP had proposed a Special Authority criteria with a view to defining a population that would benefit most from vismodegib treatment, CaTSoP had also indicated there would likely be a significant fiscal risk associated with funding of vismodegib, related to the difficulty in being able to clearly and appropriately define a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate. The Committee shared CaTSoP’s concerns regarding the difficulties with population definition and the associated potential risk of use of vismodegib beyond the intended population. Members considered this would likely be due to both variation in interpretation of the proposed Special Authority criteria and, as CaTSoP had identified, a preference for using vismodegib instead of surgery/radiotherapy should vismodegib be funded.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in practice, vismodegib may be used with alternate dosing regimens to those in the primary clinical trial evidence, such as intermittent dosing schedules with the aim of reducing toxicity. The Committee noted that evidence for use of alternate dosing approaches was poor, coming solely from anecdotal case reports.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had previously considered the application for vismodegib at its meetings in May 2015 and February 2018. At these meetings, PTAC had considered the evidence for the use of vismodegib in the treatment of locally advanced or metastatic BCC was of weak strength and quality, use was associated with significant toxicities, it was a high-cost medicine, and PTAC had recommended that funding of vismodegib for BCC patients be declined.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s careful consideration and advice about vismodegib. However, based on the difficulties objectively defining the clinical population eligible for the treatment should it be funded; the high level of fiscal and clinical risks associated with the use of this agent in a clinical population with less extreme disease manifestations; the limited evidence base; and finally the very high price sought by the supplier; the Committee did not consider that its previous recommendation regarding the funding of vismodegib should be changed.\xa0</p>', 'Status_History__c': 'a132P000000B5i0QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQMUAY'}, 'Id': 'a0P2P0000059wQMUAY', 'Event_Date__c': '2020-02-27', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BVcrQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to item 2, vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma (BCC), the Committee noted that CaTSoP had recommended funding for patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate with medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CaTSoP considered where patients are not amenable to surgery or radiotherapy, there were limited treatment options; for many patients the only treatment option was palliative care, as they would not be fit enough for chemotherapy due to age or poor health status. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that while CaTSoP had proposed a Special Authority criteria with a view to defining a population that would benefit most from vismodegib treatment, CaTSoP had also indicated there would likely be a significant fiscal risk associated with funding of vismodegib, related to the difficulty in being able to clearly and appropriately define a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate. The Committee shared CaTSoP’s concerns regarding the difficulties with population definition and the associated potential risk of use of vismodegib beyond the intended population. Members considered this would likely be due to both variation in interpretation of the proposed Special Authority criteria and, as CaTSoP had identified, a preference for using vismodegib instead of surgery/radiotherapy should vismodegib be funded.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in practice, vismodegib may be used with alternate dosing regimens to those in the primary clinical trial evidence, such as intermittent dosing schedules with the aim of reducing toxicity. The Committee noted that evidence for use of alternate dosing approaches was poor, coming solely from anecdotal case reports.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had previously considered the application for vismodegib at its meetings in May 2015 and February 2018. At these meetings, PTAC had considered the evidence for the use of vismodegib in the treatment of locally advanced or metastatic BCC was of weak strength and quality, use was associated with significant toxicities, it was a high-cost medicine, and PTAC had recommended that funding of vismodegib for BCC patients be declined.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s careful consideration and advice about vismodegib. However, based on the difficulties objectively defining the clinical population eligible for the treatment should it be funded; the high level of fiscal and clinical risks associated with the use of this agent in a clinical population with less extreme disease manifestations; the limited evidence base; and finally the very high price sought by the supplier; the Committee did not consider that its previous recommendation regarding the funding of vismodegib should be changed.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to item 2, vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma (BCC), the Committee noted that CaTSoP had recommended funding for patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate with medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CaTSoP considered where patients are not amenable to surgery or radiotherapy, there were limited treatment options; for many patients the only treatment option was palliative care, as they would not be fit enough for chemotherapy due to age or poor health status. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that while CaTSoP had proposed a Special Authority criteria with a view to defining a population that would benefit most from vismodegib treatment, CaTSoP had also indicated there would likely be a significant fiscal risk associated with funding of vismodegib, related to the difficulty in being able to clearly and appropriately define a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate. The Committee shared CaTSoP’s concerns regarding the difficulties with population definition and the associated potential risk of use of vismodegib beyond the intended population. Members considered this would likely be due to both variation in interpretation of the proposed Special Authority criteria and, as CaTSoP had identified, a preference for using vismodegib instead of surgery/radiotherapy should vismodegib be funded.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in practice, vismodegib may be used with alternate dosing regimens to those in the primary clinical trial evidence, such as intermittent dosing schedules with the aim of reducing toxicity. The Committee noted that evidence for use of alternate dosing approaches was poor, coming solely from anecdotal case reports.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had previously considered the application for vismodegib at its meetings in May 2015 and February 2018. At these meetings, PTAC had considered the evidence for the use of vismodegib in the treatment of locally advanced or metastatic BCC was of weak strength and quality, use was associated with significant toxicities, it was a high-cost medicine, and PTAC had recommended that funding of vismodegib for BCC patients be declined.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s careful consideration and advice about vismodegib. However, based on the difficulties objectively defining the clinical population eligible for the treatment should it be funded; the high level of fiscal and clinical risks associated with the use of this agent in a clinical population with less extreme disease manifestations; the limited evidence base; and finally the very high price sought by the supplier; the Committee did not consider that its previous recommendation regarding the funding of vismodegib should be changed.\xa0</p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQNUAY'}, 'Id': 'a0P2P0000059wQNUAY', 'Event_Date__c': '2020-02-27', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2020', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to item 2, vismodegib for the treatment of locally advanced or metastatic basal cell carcinoma (BCC), the Committee noted that CaTSoP had recommended funding for patients with metastatic or locally advanced BCC where surgery and/or radiation therapy are not appropriate with medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CaTSoP considered where patients are not amenable to surgery or radiotherapy, there were limited treatment options; for many patients the only treatment option was palliative care, as they would not be fit enough for chemotherapy due to age or poor health status. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that while CaTSoP had proposed a Special Authority criteria with a view to defining a population that would benefit most from vismodegib treatment, CaTSoP had also indicated there would likely be a significant fiscal risk associated with funding of vismodegib, related to the difficulty in being able to clearly and appropriately define a population for whom surgery, radiotherapy or other chemotherapy are contraindicated or inappropriate. The Committee shared CaTSoP’s concerns regarding the difficulties with population definition and the associated potential risk of use of vismodegib beyond the intended population. Members considered this would likely be due to both variation in interpretation of the proposed Special Authority criteria and, as CaTSoP had identified, a preference for using vismodegib instead of surgery/radiotherapy should vismodegib be funded.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in practice, vismodegib may be used with alternate dosing regimens to those in the primary clinical trial evidence, such as intermittent dosing schedules with the aim of reducing toxicity. The Committee noted that evidence for use of alternate dosing approaches was poor, coming solely from anecdotal case reports.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had previously considered the application for vismodegib at its meetings in May 2015 and February 2018. At these meetings, PTAC had considered the evidence for the use of vismodegib in the treatment of locally advanced or metastatic BCC was of weak strength and quality, use was associated with significant toxicities, it was a high-cost medicine, and PTAC had recommended that funding of vismodegib for BCC patients be declined.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s careful consideration and advice about vismodegib. However, based on the difficulties objectively defining the clinical population eligible for the treatment should it be funded; the high level of fiscal and clinical risks associated with the use of this agent in a clinical population with less extreme disease manifestations; the limited evidence base; and finally the very high price sought by the supplier; the Committee did not consider that its previous recommendation regarding the funding of vismodegib should be changed.\xa0</p>', 'Status_History__c': 'a132P000000BVdYQAW'}, 'change': None}]",Feb 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQHUAY'}, 'Id': 'a0P2P0000059wQHUAY', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPRQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQOUAY'}, 'Id': 'a0P2P0000059wQOUAY', 'Event_Date__c': '2020-05-25', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000Bn41QAC'}, 'change': None}]",Feb 2018,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQKUAY'}, 'Id': 'a0P2P0000059wQKUAY', 'Event_Date__c': '2018-06-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTbQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P0000059wQPUAY'}, 'Id': 'a0P2P0000059wQPUAY', 'Event_Date__c': '2020-06-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BtQyQAK'}, 'change': None}]",Jun 2018,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
